CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

203565Orig1s000

Trade Name: INJECTAFER

Generic Name: ferric carboxymaltose injection

Sponsor: Luitpold Pharmaceuticals, Inc.

Approval Date: January 17, 2013

Indications: Injectafer (ferric carboxymaltose injection) as an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients:

- who have intolerance to oral iron or have had unsatisfactory response to oral iron;
- who have non-dialysis dependent chronic kidney disease.

CENTER FOR DRUG EVALUATION AND RESEARCH

203565Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	**X**
Labeling	**X**
REMS	
Summary Review	**X**
Officer/Employee List	**X**
Office Director Memo	
Cross Discipline Team Leader Review	**X**
Medical Review(s)	**X**
Chemistry Review(s)	**X**
Environmental Assessment	
Pharmacology Review(s)	**X**
Statistical Review(s)	**X**
Microbiology Review(s)	**X**
Clinical Pharmacology/Biopharmaceutics Review(s)	**X**
Other Reviews	**X**
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	**X**
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

203565Orig1s000

APPROVAL LETTER

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 203565

NDA APPROVAL

Luitpold Pharmaceuticals, Inc.
Attention: Marsha E. Simon
Sr. Manager, Regulatory Affairs
800 Adams Avenue, Suite 100
Norristown, PA 19403

Dear Ms. Simon:

Please refer to your New Drug Application (NDA) dated September 30, 2011, received October 3, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for INJECTAFER (ferric carboxymaltose injection).

We acknowledge receipt of your amendments dated November 15; December 5 and 13, 2011; January 6 and 11; February 8; March 26; April 13, 23, 24, and 27; May 16; June 6 and 25; July 18; September 13; October 29; and December 5, 2012; January 30; February 5; March 13 and 20; April 2 and 12; May 6 and 31; June 13; and July 2, 16 (2), 17, 19, 22 (2) and 24, 2013.

The January 30, 2013, submission constituted a complete response to our July 23, 2012, action letter.

This new drug application provides for the use of INJECTAFER (ferric carboxymaltose injection) as an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients:

- who have intolerance to oral iron or have had unsatisfactory response to oral iron;
- who have non-dialysis dependent chronic kidney disease.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE-CONTAINER LABELS

We acknowledge your July 22, 2013, submission containing final printed carton and container labels.

CARTON AND IMMEDIATE-CONTAINER LABELS

Submit final printed carton and immediate-container labels that are identical to the carton and immediate-container labels submitted on July 22, 2013, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Carton and Container Labels for approved NDA 203565**." Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

ADVISORY COMMITTEE

Your application for INJECTAFER (ferric carboxymaltose injection) was not referred to an FDA advisory committee because this drug is not the first in its class, the safety profile is similar to that of other drugs approved for this indication, and the application did not raise significant safety or efficacy issues that were unexpected for a drug/biologic of this class.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to 1 years because necessary studies are impossible or highly impracticable due to the infrequency of the condition in this age group.

We are deferring submission of your pediatric studies for ages 1 to 17 years for this application because this product is ready for approval for use in adults and the pediatric studies have not been completed.

Your deferred pediatric studies required by section 505B(a) of the FDCA are required postmarketing studies. The status of these postmarketing studies must be reported annually according to 21 CFR 314.81 and section 505B(a)(3)(B) of the FDCA. These required studies are listed below.

2064-1 Identify an optimal dose of INJECTAFER (ferric carboxymaltose injection) for the pediatric patient population. Conduct one or more pharmacokinetic (PK) and pharmacodynamic (PD) trials in pediatric patients aged 1 to <17 years with iron deficiency anemia sufficient to justify and to characterize the dose to be tested in a confirmatory clinical trial of safety and efficacy. Identify the most relevant PD endpoints to measure.

Final Protocol Submission:	07/2014
Trial Completion:	07/2016
Final Report Submission:	07/2017

2064-2 Determine the safety and efficacy of INJECTAFER (ferric carboxymaltose injection) in pediatric patients aged 1 to <17 years with iron deficiency anemia by conducting a randomized, active-controlled clinical trial.

Final Protocol Submission:	01/2017
Trial Completion:	01/2020
Final Report Submission:	01/2021

Submit the protocols to your IND 063243, with a cross-reference letter to this NDA.

Reports of these required pediatric postmarketing studies must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED**

PEDIATRIC ASSESSMENTS" in large font, bolded type at the beginning of the cover letter of the submission.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

METHODS VALIDATION

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

EXPIRATION DATING

An expiration dating period of 24 months is granted for the drug product, when stored at 25°C (77°F) excursions permitted between 15°C to 30°C (59°F to 86°F).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Amy Baird, Regulatory Project Manager, at (301) 796-4969.

Sincerely,

{See appended electronic signature page}

Edvardas Kaminskas, M.D.
Deputy Director
Division of Hematology Products
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

Enclosure(s):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

EDVARDAS KAMINSKAS
07/25/2013